Corcept Therapeutics (NASDAQ:CORT) Insider William Guyer Sells 20,000 Shares

Key Points

• Insider sale: Director William Guyer sold 20,000 shares on April 7 at an average price of $40.97 under a pre‑arranged Rule 10b5‑1 plan, leaving him with 2,231 shares and representing an ~89.96% reduction in his holdings after multiple recent sales.
• Earnings miss: Corcept reported $0.20 EPS vs. $0.33 expected and revenue of $202.13M vs. $254.94M expected, although revenue was up 11.1% year‑over‑year.
• Market and analyst context: Shares traded near $41.87 (1‑year range $28.66–$91.00) with a $4.45B market cap, and analysts hold a consensus Moderate Buy rating with an average price target of $77.67.

Corcept Therapeutics Incorporated (NASDAQ:CORT - Get Free Report) insider William Guyer sold 20,000 shares of the business's stock in a transaction on Tuesday, April 7th. The stock was sold at an average price of $40.97, for a total value of $819,400.00. Following the transaction, the insider owned 2,231 shares in the company, valued at approximately $91,404.07. This trade represents a 89.96% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

William Guyer also recently made the following trade(s):

• On Friday, March 20th, William Guyer sold 11,767 shares of Corcept Therapeutics stock. The shares were sold at an average price of $36.01, for a total value of $423,729.67.
• On Wednesday, March 4th, William Guyer sold 8,233 shares of Corcept Therapeutics stock. The shares were sold at an average price of $35.99, for a total value of $296,305.67.
• On Tuesday, February 3rd, William Guyer sold 20,000 shares of Corcept Therapeutics stock. The shares were sold at an average price of $40.87, for a total transaction of $817,400.00.

Corcept Therapeutics Trading Up 0.4%

Corcept Therapeutics stock traded up $0.18 during mid-day trading on Wednesday, hitting $41.87. The company's stock had a trading volume of 1,607,270 shares, compared to its average volume of 2,134,427. Corcept Therapeutics Incorporated has a 1 year low of $28.66 and a 1 year high of $91.00. The stock's fifty day moving average is $37.54 and its two-hundred day moving average is $58.83. The firm has a market capitalization of $4.45 billion, a PE ratio of 51.06 and a beta of 0.25. The company has a current ratio of 2.92, a quick ratio of 2.85 and a debt-to-equity ratio of 0.01.

Corcept Therapeutics (NASDAQ:CORT - Get Free Report) last announced its earnings results on Tuesday, February 24th. The biotechnology company reported $0.20 earnings per share for the quarter, missing the consensus estimate of $0.33 by ($0.13). Corcept Therapeutics had a return on equity of 15.19% and a net margin of 12.96%.The company had revenue of $202.13 million for the quarter, compared to analysts' expectations of $254.94 million. During the same period last year, the business earned $0.26 EPS. The company's quarterly revenue was up 11.1% compared to the same quarter last year. On average, analysts anticipate that Corcept Therapeutics Incorporated will post 1.36 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the stock. Advisory Services Network LLC acquired a new stake in shares of Corcept Therapeutics in the 3rd quarter valued at about $25,000. Clearstead Advisors LLC boosted its stake in Corcept Therapeutics by 163.6% during the 3rd quarter. Clearstead Advisors LLC now owns 311 shares of the biotechnology company's stock worth $26,000 after purchasing an additional 193 shares during the period. Hantz Financial Services Inc. grew its position in Corcept Therapeutics by 598.5% during the 3rd quarter. Hantz Financial Services Inc. now owns 461 shares of the biotechnology company's stock worth $38,000 after purchasing an additional 395 shares during the last quarter. Larson Financial Group LLC increased its stake in Corcept Therapeutics by 2,326.3% in the third quarter. Larson Financial Group LLC now owns 461 shares of the biotechnology company's stock valued at $38,000 after purchasing an additional 442 shares during the period. Finally, Gould Capital LLC increased its stake in Corcept Therapeutics by 50.0% in the third quarter. Gould Capital LLC now owns 600 shares of the biotechnology company's stock valued at $50,000 after purchasing an additional 200 shares during the period. 93.61% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research analysts have recently commented on CORT shares. Zacks Research lowered shares of Corcept Therapeutics from a "hold" rating to a "strong sell" rating in a research note on Tuesday, January 13th. Weiss Ratings reiterated a "hold (c)" rating on shares of Corcept Therapeutics in a research note on Monday, December 29th. Wolfe Research raised shares of Corcept Therapeutics from an "underperform" rating to a "peer perform" rating in a report on Thursday, March 26th. HC Wainwright lowered their price target on shares of Corcept Therapeutics from $67.00 to $60.00 and set a "buy" rating for the company in a report on Wednesday, March 25th. Finally, Canaccord Genuity Group increased their target price on Corcept Therapeutics from $100.00 to $110.00 and gave the company a "buy" rating in a report on Thursday, March 26th. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, Corcept Therapeutics currently has a consensus rating of "Moderate Buy" and an average price target of $77.67.

About Corcept Therapeutics

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company's scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company's flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing's syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.